A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity

Completed · Phase 2 · Has a placebo group

Conditions studied: Obesity

In brief

This study will evaluate the efficacy, safety, and tolerability of GLY-200 in participants with obesity.

Key facts

Study ID

NCT06259981

Run by

Glyscend, Inc.

People needed

75

Starts

2024-05-20

Expected to finish

2024-10-23

Last updated by the study team

2025-01-23

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female, ≥ 18 and ≤ 70 years old at the time of screening
• BMI ≥ 32 and ≤ 40 kg/m² at screening

You may not qualify if…

• Known history of any form of diabetes mellitus, or HbA1c ≥6.5% (48 mmol/mol)
• Participants who have had an increase or decrease in body weight more than 5% within the last 3 months
• Treated with any prescription medication or procedure that promotes weight loss or weight gain in the last 6 months
• Use of any drug treatment that affects gastric pH
• Use of any drug treatment that affects gastrointestinal motility
• Diagnosis or treatment of any symptomatic or structural abnormality of the GI tract or active disease within 12 months
• Clinically significant symptoms (as determined by the Investigator) of nausea, vomiting, bloating, diarrhea, flatulence, constipation, or abdominal pain in the last 30 days

Where it is running

• Tampa Bay Medical Research, Inc. — Clearwater, Florida, United States
• Sensible Healthcare, LLC — Ocoee, Florida, United States
• Tandem Clinical Research — Marrero, Louisiana, United States
• Mercury Street Medical — Butte, Montana, United States
• Clinical Trials of Texas, Inc. — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.